Title

Phase-I Trial of Dose-Intense Liposome-Encapsulated Doxorubicin in Patients with Advanced Sarcoma

Publication Type

Journal Article

Publication Date

1997

Abstract

To define the maximum-tolerated dose (MTD) of liposome-encapsulated doxorubicin (LED) when used every 2 weeks with granulocyte colony-stimulating factor (G-CSF) in patients with advanced soft tissue sarcoma. Patients and Methods: Doxorubicin encapsulated in egg phosphatidylcholine/cholesterol liposomes was given to patients with sarcoma in a disease-specific phase I trial. The initial dose was 75 mg/m2 with G-CSF 5 ?g/kg. The MTD was defined as the highest dose that could be given every 2 weeks. Results: Twenty-nine patients participated in this study. Major toxicities included myelosuppression, nausea and vomiting, fatigue, and mucositis. Eight patients were hospitalized for nadir fever. No cardiotoxicity was seen. The MTD was LED 105 mg/m2 with G-CSF 5 ?g/kg. LED 120 mg/m2 resulted in tolerable, albeit prominent, acute toxicity, but did not permit recycling of therapy on day 15. Among 26 patients with soft tissue sarcoma, 23 had measurable disease, of whom three achieved a partial response (13%; 95% confidence interval, 2% to 34%). Conclusion: LED can be administered every 2 weeks at a dose of 105 mg/m2 with G-CSF support, which provides a dose-intensity of 52.5 mg/m2/wk. To exceed this intensity, the dose of LED that would have to be administered every 3 weeks would be greater than 157.5 mg/ m2. A formal phase II trial is needed to estimate better the true response rate.

Discipline

Econometrics | Medicine and Health Sciences

Research Areas

Econometrics

Publication

Journal of Clinical Oncology

Volume

15

Issue

5

First Page

2111

Last Page

2117

ISSN

0732-183X

Publisher

Lippincott Williams and Wilkins

Additional URL

http://jco.ascopubs.org/cgi/content/abstract/15/5/2111

This document is currently not available here.

Share

COinS